Insurance companies aren't the only ones who stand to benefit
from healthcare for all. Providers like DaVita will be able
to help more sick patients under the new plan and in turn generate
They are the premier kidney care provider in America and serve
the more than 400,000 people in need of their services. They
are looking to expand their services over the coming years which
should prove to be a profitable venture according to analysts.
Studies have shown that many on dialysis are not getting enough
treatment. This is not only true here, but abroad as well.
DaVita is working to make treatment easier, cheaper and more
convenient. They are growing fast and their stock price is
doing the same.
Company Description & Developments
DaVita currently operates or provides administrative services to
approximately 1400 outpatient dialysis centers located in 43 states
and the District of Columbia, serving approximately 110,000
The company was recently upgraded to buy at Zacks Equity
Research. They cited strong cash flow and strategic
acquisitions. Just yesterday, DaVita announced a majority
stake in Nephrolife India. This is a longer term strategic
move to expand their services globally.
It's important to note that DaVita has achieved clinical
outcomes for patients that have improved year-over-year for more
than a decade. They are making people's lives better not only
with their products, but also through education, prescription
management and assistance with everything from traveling to home
DaVita is a mid-cap company (7.56 billion) that is trading at about
17 times trailing earnings (P/E). Looking forward, Zacks
Consensus Estimates are calling for that number to drop to 13 with
no change in price from these levels.
DaVita hit the Zacks Rank 1 Strong Buy list just yesterday from
a rank of 2. It has been a buy (Rank 2) since Jan 5, 2011
DaVita reported a 5.63% quarterly sales increase at their last
earnings report on November 3, 2011.
They saw year over year sales growth of 9.46% and a 26% rise in
earnings per share in the same period with total sales of roughly
6.4 billion in FY2010. DaVita is expected to earn $5.05 in
FY2011 according to the Zacks Consensus Estimate.
We saw one analyst revise next quarter's earnings estimates up
within the past month. The others have stood firm on their
estimates to date. DaVita will report Q4 results on February
16th. Expectations are for DaVita to generate $1.48 in income this
quarter. Of the 13 analysts who cover DaVita, the consensus
is for the company to grow earnings by 15.38% in FY2011 with
another jump of 23.03% in FY2012.
In terms of the magnitude of analyst estimate trends, we are
seeing all of the consensus estimates higher than they were 90 days
ago from current quarter, out to FY 2012. It's important to
note that revisions have not been dramatically higher.
DaVita missed estimates last quarter by 0.68%, with the average
earnings surprise being a positive 0.97% over the past year.
It seems as though analysts tend to be one point with their
estimates in DVA.
Market Performance & Technicals
The chart for DaVita has gotten particularly strong over the past
three months. DVA has been up for five trading days and has
been riding along the upper edge of its Bollinger band. This
action leads me to believe that we should see a pullback soon,
which would present an opportunity to ride this recent
DVA has remained above its 50 day moving average since early
November. The stock is about $8.00 away from its 52 week high
of $89.76 which was made back in July of 2011.
The stock just broke above its 200 day moving average of $77.63,
which is the first time since August of 2011. I would watch
this level for support and if DVA breaks below it, we might see
further selling down to the 50 day average of $75.84.
DaVita has outpaced the S&P 500 by 8.17% over the past year
and almost 10% over the last twelve weeks. DVA has kept up
its momentum, jumping ahead of the S&P's performance by 2%
during the last month.
It might be smart to wait for the pullback before moving into
Jared A Levy is the Momentum Stock Strategist for Zacks.com. He
is also the Editor in charge of the market-beating
Zacks Whisper Trader Service.
DAVITA INC (
): Free Stock Analysis Report
To read this article on Zacks.com click here.